Role of Bradykinin in Mediating Vascular Effects of Angiotensin-Converting Enzyme Inhibitors in Humans
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background The angiotensin-converting enzyme (ACE) not only generates angiotensin II but is also the main enzyme that destroys bradykinin. It has been hypothesized, therefore, that bradykinin is involved in the vascular effects of ACE inhibitors. However, its contribution has never been demonstrated in humans because of the lack of specific bradykinin receptor antagonists. Methods and Results High-resolution ultrasound and Doppler were used to measure radial artery diameter and blood flow in 10 healthy volunteers. The vascular effects of the ACE inhibitor quinaprilat, the selective bradykinin B 2 -receptor antagonist icatibant, and their combination were determined at rest, during reactive hyperemia (with increased flow causing endothelium-mediated, flow-dependent dilation), and during sodium nitroprusside, causing endothelium-independent dilation. Neither icatibant nor quinaprilat affected arterial diameter or blood flow at rest. However, icatibant reduced flow-dependent dilation by 33%, and quinaprilat increased flow-dependent dilation over baseline by 46%. After coinfusion of quinaprilat and icatibant, flow-dependent dilation was reduced to a similar extent as after infusion of icatibant alone. Conclusions ACE inhibition enhances flow-dependent, endothelium-mediated dilation in humans by a bradykinin-dependent mechanism. This observation indicates that accumulation of endogenous bradykinin is involved in the vascular effects of ACE inhibitors in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Joannides, R., Haefeli, W. E., Linder, L., Richard, V., Bakkali, E. H., Thuillez, C., & Lüscher, T. F. (1995) · Circulation · doi:10.1161/01.cir.91.5.1314 · Cited by 1,622
Hoe 140 a new potent and long acting bradykinin‐antagonist:in vivo studies
Wirth, K., Hock, F. J., Albus, U., Linz, W., Alpermann, H. G., Anagnostopoulos, H., Henke, S., Breipohl, G., König, W., Knolle, J., et al. (1991) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1991.tb12249.x · Cited by 830
Yusuf, S., Pepine, C. J., Garces, C., Pouleur, H., Rousseau, M., Salem, D., Kostis, J., Benedict, C., Bourassa, M., & Pitt, B. (1992) · The Lancet · doi:10.1016/0140-6736(92)92889-n · Cited by 666
Physical Training Improves Endothelial Function in Patients With Chronic Heart Failure
Hornig, B., Maier, V., & Drexler, H. (1996) · Circulation · doi:10.1161/01.cir.93.2.210 · Cited by 627
Self-citationWiemer, G., Schölkens, B. A., Becker, R. H., & Busse, R. (1991) · Hypertension · doi:10.1161/01.hyp.18.4.558 · Cited by 349
Pörsti, I., Bara, A. T., Busse, R., & Hecker, M. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb14787.x · Cited by 239
Mombouli, J. V., Illiano, S., Nagao, T., Scott-Burden, T., & Vanhoutte, P. M. (1992) · Circulation Research · doi:10.1161/01.res.71.1.137 · Cited by 223
Role of Endogenous Bradykinin in Human Coronary Vasomotor Control
Groves, P., Kurz, S., Just, H., & Drexler, H. (1995) · Circulation · doi:10.1161/01.cir.92.12.3424 · Cited by 205
Self-citationKiowski, W., Linder, L., Kleinbloesem, C. H., van Brummelen, P., & Bühler, F. R. (1992) · Circulation · doi:10.1161/01.cir.85.1.1 · Cited by 141
Cited by
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958
Assessment and treatment of endothelial dysfunction in humans
Anderson, T. J. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00259-4 · Cited by 443
Gainer, J. V., Morrow, J. D., Loveland, A., King, D. J., & Brown, N. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810293391804 · Cited by 443
Drugs targeting the renin–angiotensin–aldosterone system
Zaman, M. A., Oparil, S., & Calhoun, D. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd873 · Cited by 439
Anderson, T. J., Elstein, E., Haber, H., & Charbonneau, F. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00537-9 · Cited by 363
Maggioni, A. P., Anand, I., Gottlieb, S. O., Latini, R., Tognoni, G., & Cohn, J. N. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02304-5 · Cited by 356
“The mechanisms of the beneficial effect of ACE inhibitors are not fully established, but it is likely that inhibition of angiotensin II production is at least partially responsible (2,3).”
BackgroundHornig, B., Landmesser, U., Kohler, C., Ahlersmann, D., Spiekermann, S., Christoph, A., Tatge, H., & Drexler, H. (2001) · Circulation · doi:10.1161/01.cir.103.6.799 · Cited by 341
Self-citation(2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.003 · Cited by 331
Swedberg, K., Pfeffer, M., Granger, C., Held, P., Mcmurray, J., Ohlin, G., Olofsson, B., Östergren, J., & Yusuf, S. (1999) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(99)90013-1 · Cited by 294
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
Microdroplet fusion mass spectrometry for fast reaction kinetics
Lee, J. K., Kim, S., Nam, H. G., & Zare, R. N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503689112 · Cited by 268
Roman, M. J., Naqvi, T. Z., Gardin, J. M., Gerhard-Herman, M., Jaff, M., & Mohler, E. (2006) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2006.04.020 · Cited by 264
Dzau, V. J., Bernstein, K., Celermajer, D., Cohen, J., Dahlöf, B., Deanfield, J., Diez, J., Drexler, H., Ferrari, R., van Gilst, W., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01878-1 · Cited by 259
Self-citationAgnoletti, L., Curello, S., Bachetti, T., Malacarne, F., Gaia, G., Comini, L., Volterrani, M., Bonetti, P., Parrinello, G., Cadei, M., et al. (1999) · Circulation · doi:10.1161/01.cir.100.19.1983 · Cited by 233
Niskanen, L., Hedner, T., Hansson, L., Lanke, J., Niklason, A., & for the CAPPP study group (2001) · Diabetes Care · doi:10.2337/diacare.24.12.2091 · Cited by 219
Losartan Increases Bradykinin Levels in Hypertensive Humans
Campbell, D. J., Krum, H., & Esler, M. D. (2005) · Circulation · doi:10.1161/01.cir.0000153269.07762.3b · Cited by 184
The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins
Blais, C., Marceau, F., Rouleau, J.-L., & Adam, A. (2000) · Peptides · doi:10.1016/s0196-9781(00)00348-x · Cited by 135
Krombach, R. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00050-9 · Cited by 40
Correale, M., Mazzeo, P., Tricarico, L., Croella, F., Fortunato, M., Magnesa, M., Amatruda, M., Alfieri, S., Ferrara, S., Ceci, V., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01166-2 · Cited by 14
Metadata
- Authors
- Hornig, B., Kohler, C., & Drexler, H.
- Venue
- Circulation
- Published
- 1997-03-04
- Volume
- 95
- Issue
- 5
- Pages
- 1115-1118
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1993013099
- Cited by
- 333
- References
- 15
- FWCI
- 17.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.